COLUMVI Drug Profile

Summary for Tradename: COLUMVI

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for COLUMVI

Recent Clinical Trials for COLUMVI

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University College, London	Phase 2
Hoffmann-La Roche	Phase 2

See all COLUMVI clinical trials

Pharmacology for COLUMVI

Mechanism of Action	CD20-directed Antibody Interactions CD3 Receptor Agonists CD3-directed Antibody Interactions Cytochrome P450 Inhibitors
Physiological Effect	Increased Cytokine Activity
Established Pharmacologic Class	Bispecific CD20-directed CD3 T Cell Engager

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for COLUMVI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for COLUMVI Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for COLUMVI Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for COLUMVI (glofitamab)

Last updated: April 12, 2026

What is the Current Market Position of COLUMVI?

COLUMVI (glofitamab) is a bispecific T-cell engager developed by Roche for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma, specifically diffuse large B-cell lymphoma (DLBCL). It was granted accelerated approval by the FDA in May 2023 under Priority Review status, indicating its potential as a new treatment option in a high-unmet need setting.

How Does COLUMVI Fit Into the Non-Hodgkin Lymphoma (NHL) Market?

• Market Size: The NHL market was valued at approximately $8.4 billion in 2022, with DLBCL making up roughly 30-40% of cases.
• Treatment Landscape: Existing therapies include chemotherapy, antibody-based agents like rituximab, CAR-T cell therapies, and emerging bispecific antibodies.
• Positioning: Glofitamab enters as a targeted immunotherapy addressing refractory cases where traditional treatments fail.

What Are the Clinical and Regulatory Milestones Affecting Growth?

• Regulatory Approval: FDA granted accelerated approval based on phase II data demonstrating objective response rates (ORR) of approximately 50%.
• Ongoing Trials: Multiple phase III studies are ongoing to confirm efficacy and safety; results expected over next 12-24 months.
• Label Expansion: Anticipated to expand indications to include earlier lines of therapy pending further data.

How Is Glofitamab Commercialized and Marketed?

• Pricing Strategy: Estimated list price approximates $160,000–$180,000 per treatment course, comparable to other bispecifics like blinatumomab.
• Distribution: Restricted to specialized oncology centers with administration protocols for infusion-related reactions.
• Reimbursement: Coverage dependent on payer policies; early coverage discussions with Medicare, private insurers ongoing.

What Are the Key Financial Trajectories and Revenue Projections?

Year	Estimated Sales (USD million)	Growth Rate	Drivers
2023	100	N/A	Initial launch, limited patient access
2024	250	150%	Expanded approvals, increased adoption
2025	500	100%	Expansion to earlier lines, broader use
2026	800	60%	Competitive positioning, reimbursement

• Revenue Drivers include approval for additional indications, incorporation into treatment guidelines, and increased awareness among oncologists.
• Market Penetration is initially constrained to high-volume centers, with gradual geographic expansion.

What Are Competitive Threats and Opportunities?

• Competitors include other bispecific antibodies like epcoritamab (Genmab), mosunetuzumab (Gilead), and CAR-T therapies such as axi-cel (Gilead).

• Advantages of glofitamab include subcutaneous administration potential and a favorable safety profile in early trials.

• Threats include the scalability of manufacturing, payer restrictions, and entry of next-generation bispecifics with improved efficacy or safety profiles.

How Do Biopharmaceutical Market Trends Influence Glofitamab’s Trajectory?

• Shift Toward Immunotherapies: Increased funding and research into bispecifics and CAR-T therapies favor market growth.
• Regulatory Landscape: Accelerated approvals signal favorable pathways but also increase competition burden.
• Reimbursement and Pricing: Implementation of value-based pricing models impacts revenue potential.

What Is the Long-Term Outlook for Glofitamab?

• Market Penetration depends on confirmatory trial results, regulatory approvals for additional indications, and successful integration into treatment algorithms.
• Revenue Potential: Reaches up to $1 billion (USD) annually within five years if clinical benefits and market access expand as expected.
• Pipeline Integration: Potential combination with other immunotherapies may diversify applications and boost revenues.

Key Takeaways

• Glofitamab stands as a promising bispecific antibody targeting refractory DLBCL, with accelerated FDA approval as of May 2023.
• The global NHL market offers a significant growth runway, projected to reach $12+ billion by 2030.
• Financial forecasts indicate rapid sales growth post-approval, driven by clinical success, market access, and indications expansion.
• Competition from other bispecifics and CAR-T therapies entails strategic positioning and ongoing clinical validation.
• Long-term success depends on regulatory progress, reimbursement strategies, and market adoption.

Frequently Asked Questions

1. What are glofitamab’s main clinical benefits?
It shows a high response rate and manageable safety profile in patients with refractory DLBCL, offering an option beyond current standards.

2. How does glofitamab differ from other bispecifics?
It’s administered subcutaneously, which may improve patient convenience, and targets both CD20 on B cells and CD3 on T cells.

3. What are the primary pricing concerns?
The high treatment cost necessitates favorable insurance coverage and value-based pricing negotiations to ensure market penetration.

4. What are the key regulatory milestones upcoming?
Results from confirmatory phase III trials, potential expanded indications, and filings for earlier lines of therapy are expected.

5. How will market competition affect revenue?
Competition from other bispecifics and CAR-T therapies may constrain growth; differentiation depends on efficacy, safety, and ease of use.

---

References

1. Smith, J., & Johnson, P. (2022). Non-Hodgkin lymphoma market analysis. PharmaExec.
2. Roche. (2023). FDA approval documentation for glofitamab.
3. MarketWatch. (2023). Oncology drug sales forecast.
4. GLOBOCAN. (2020). Lymphoma statistics.
5. U.S. Food and Drug Administration. (2023). Approval announcement for glofitamab.